Swedbank AB raised its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 6.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,140,316 shares of the company’s stock after purchasing an additional 122,900 shares during the quarter. Swedbank AB owned 0.12% of AbbVie worth $367,107,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors also recently added to or reduced their stakes in the company. Vermillion & White Wealth Management Group LLC purchased a new position in shares of AbbVie in the fourth quarter valued at $26,000. IFS Advisors LLC purchased a new position in AbbVie during the first quarter valued at approximately $36,000. Redmont Wealth Advisors LLC bought a new position in AbbVie in the 1st quarter valued at $37,000. Able Wealth Management LLC bought a new position in AbbVie in the 4th quarter valued at $33,000. Finally, Valued Wealth Advisors LLC grew its position in shares of AbbVie by 111.1% during the 1st quarter. Valued Wealth Advisors LLC now owns 228 shares of the company’s stock valued at $42,000 after purchasing an additional 120 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.
Insider Buying and Selling
In related news, Chairman Richard A. Gonzalez sold 66,500 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $186.52, for a total value of $12,403,580.00. Following the completion of the transaction, the chairman now directly owns 446,599 shares of the company’s stock, valued at $83,299,645.48. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other AbbVie news, Chairman Richard A. Gonzalez sold 282,845 shares of the stock in a transaction on Wednesday, July 17th. The stock was sold at an average price of $175.00, for a total value of $49,497,875.00. Following the completion of the transaction, the chairman now owns 513,099 shares in the company, valued at $89,792,325. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman Richard A. Gonzalez sold 66,500 shares of the business’s stock in a transaction on Monday, August 5th. The shares were sold at an average price of $186.52, for a total transaction of $12,403,580.00. Following the sale, the chairman now owns 446,599 shares in the company, valued at approximately $83,299,645.48. The disclosure for this sale can be found here. 0.25% of the stock is currently owned by insiders.
Analysts Set New Price Targets
View Our Latest Research Report on AbbVie
AbbVie Trading Up 0.3 %
NYSE:ABBV traded up $0.50 during midday trading on Friday, reaching $193.90. 3,662,784 shares of the stock traded hands, compared to its average volume of 5,535,780. The stock has a market capitalization of $342.40 billion, a P/E ratio of 57.28, a PEG ratio of 2.49 and a beta of 0.64. AbbVie Inc. has a 12 month low of $135.85 and a 12 month high of $194.99. The company has a debt-to-equity ratio of 7.93, a quick ratio of 0.83 and a current ratio of 0.94. The company has a fifty day moving average of $175.56 and a 200 day moving average of $171.94.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Thursday, July 25th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.08. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.02 billion. AbbVie had a net margin of 9.71% and a return on equity of 186.82%. AbbVie’s revenue for the quarter was up 4.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.91 earnings per share. On average, research analysts predict that AbbVie Inc. will post 10.87 EPS for the current year.
AbbVie Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Thursday, August 15th. Investors of record on Monday, July 15th were issued a dividend of $1.55 per share. The ex-dividend date was Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.20%. AbbVie’s dividend payout ratio is presently 183.98%.
AbbVie Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Recommended Stories
- Five stocks we like better than AbbVie
- How to Use High Beta Stocks to Maximize Your Investing Profits
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Learn Technical Analysis Skills to Master the Stock Market
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.